Last checked at 3 Jul 2012 07:00
FOR IMMEDIATE RELEASE 3 JULY 2012
ImmuPharma PLC
Appointment of Cenkos Securities as Joint Broker
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immediate effect.
Commenting on the appointment of Cenkos, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer said: "We are delighted to be working more closely with Cenkos. The Cenkos team brings a wealth of experience within the capital markets arena as well as a strong franchise in healthcare which should be invaluable for ImmuPharma through this next important stage of our development where we are focusing on advancing our lead compounds in Lupus and Cancer and also further strengthening our shareholder relationships. The proactive approach that Cenkos has with regards to marketing its corporate stocks combined with its high level analyst research will undoubtedly add a positive dimension to this strategy."
For further information please contact:
ImmuPharma PLC | |
Dimitri Dimitriou, Chief Executive Officer | +44 20 7152 4080 |
Lisa Baderoon, Head of Investor Relations | +44 7721 413 496 |
Buchanan | + 44 20 7466 5000 |
Mark Court | |
Cenkos Securities plc | +44 20 7397 8900 |
Stephen Keys, Camilla Hume (Corporate Finance) Andy Roberts (Sales) |